Trials / Withdrawn
WithdrawnNCT04649710
A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants
A Double-Blind, Multicenter, Placebo-Controlled, Randomized, Parallel, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and drug level of Pegbelfermin in healthy overweight and obese Chinese and Korean participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BMS-986036 | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2021-06-21
- Primary completion
- 2021-09-21
- Completion
- 2021-09-22
- First posted
- 2020-12-02
- Last updated
- 2022-04-28
Locations
2 sites across 2 countries: China, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04649710. Inclusion in this directory is not an endorsement.